Therapy of intermediate uveitis

被引:2
|
作者
Doycheva, D. [1 ]
Deuter, C. [1 ]
Zierhut, M. [1 ]
机构
[1] Univ Augenklin Tubingen, D-72076 Tubingen, Germany
来源
OPHTHALMOLOGE | 2014年 / 111卷 / 12期
关键词
Corticosteroids; Immunosuppressive agents; Biologics; Inflammation; Vitreous body; CHRONIC NONINFECTIOUS UVEITIS; INTRAVITREAL BEVACIZUMAB AVASTIN; JUVENILE IDIOPATHIC ARTHRITIS; REFRACTORY MACULAR EDEMA; POSTERIOR UVEITIS; TRIAMCINOLONE ACETONIDE; MYCOPHENOLATE-MOFETIL; CHILDHOOD UVEITIS; CYCLOSPORINE; INFLAMMATION;
D O I
10.1007/s00347-014-3201-2
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Intermediate uveitis is a form of intraocular inflammation in which the vitreous body is the major site of inflammation. Intermediate uveitis is primarily treated medicinally and systemic corticosteroids are the mainstay of therapy. When recurrence of uveitis or side effects occur during corticosteroid therapy an immunosuppressive treatment is required. Cyclosporine A is the only immunosuppressive agent that is approved for therapy of uveitis in Germany; however, other immunosuppressive drugs have also been shown to be effective and well-tolerated in patients with intermediate uveitis. In severe therapy-refractory cases when conventional immunosuppressive therapy has failed, biologics can be used. In patients with unilateral uveitis or when the systemic therapy is contraindicated because of side effects, an intravitreal steroid treatment can be carried out. In certain cases a vitrectomy may be used.
引用
收藏
页码:1219 / 1232
页数:14
相关论文
共 50 条
  • [41] Optimising drug therapy for non-infectious uveitis
    Mohammad Ali Shahab
    Tahreem Aman Mir
    Sidra Zafar
    International Ophthalmology, 2019, 39 : 1633 - 1650
  • [42] Early Infliximab Therapy for Sight Threatening Posterior Uveitis
    Adan Civera, A.
    Pelegrin, L.
    Llorens, V.
    Mesquida, M.
    Hernandez, M.
    Espinosa, G.
    Cervera, R.
    Sanmarti, R.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2010, 51 (13)
  • [43] Overview and recent developments in the medical management of paediatric uveitis
    Pilly, Bertrand
    Heath, Greg
    Tschuor, Patrizia
    Lightman, Susan
    Gale, Richard P.
    EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (13) : 1787 - 1795
  • [44] Therapeutic advances in juvenile idiopathic arthritis - associated uveitis
    Gueudry, Julie
    Touhami, Sara
    Quartier, Pierre
    Bodaghi, Bahram
    CURRENT OPINION IN OPHTHALMOLOGY, 2019, 30 (03) : 179 - 186
  • [45] Anti-tubercular therapy in the treatment of tubercular uveitis: A systematic review and meta-analysis
    Betzler, Bjorn Kaijun
    Putera, Ikhwanuliman
    Testi, Ilaria
    Nora, Rina La Distia
    Kempen, John
    Kon, Onn Min
    Pavesio, Carlos
    Gupta, Vishali
    Agrawal, Rupesh
    OPHTHALMOLOGY, 2023, 68 (02) : 241 - 256
  • [46] Managing juvenile idiopathic arthritis-associated uveitis
    Hawkins, Madeleine J.
    Dick, Andrew D.
    Lee, Richard J. W.
    Ramanan, Athimalaipet V.
    Carreno, Ester
    Guly, Catherine M.
    Ross, Adam H.
    SURVEY OF OPHTHALMOLOGY, 2016, 61 (02) : 197 - 210
  • [47] Local versus Systemic Therapy for Noninfectious Uveitis (NIU)
    Chang, Eileen L.
    Sobrin, Lucia
    SEMINARS IN OPHTHALMOLOGY, 2023, 38 (01) : 15 - 23
  • [48] Nonsteroidal drugs for the treatment of noninfectious posterior and intermediate uveitis
    Imrie, Fraser R.
    Dick, Andrew D.
    CURRENT OPINION IN OPHTHALMOLOGY, 2007, 18 (03) : 212 - 219
  • [49] Efficacy and safety of immunomodulatory drugs in patients with non-infectious intermediate and posterior uveitis, panuveitis and macular edema: A systematic literature review
    Gomez-Gomez, Alejandro
    Loza, Estibaliz
    Rosario, M. Piedad
    Espinosa, Gerard
    de Morales, Jose M. Garcia Ruiz
    Herrera, Jose M.
    Munoz-Fernandez, Santiago
    Rodriguez-Rodriguez, Luis
    Cordero-Coma, Miguel
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2020, 50 (06) : 1299 - 1306
  • [50] Future for biological therapy for uveitis
    Rosenbaum, James T.
    CURRENT OPINION IN OPHTHALMOLOGY, 2010, 21 (06) : 473 - 477